Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANNOAC-VTE: Head-to-Head NOAC Comparison
NCT03129555Phase 4Active, not recruiting
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Apr 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of edoxaban, apixaban, rivaroxaban, dabigatran etexilate oral solution in venous thromboembolism (VTE), sponsored by Herlev & Gentofte Hospital. Started Apr 2023; status: active, not recruiting.
02
Drugs
edoxabanapixabanrivaroxabandabigatran etexilate oral solution
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03129555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129555.